Immutep (IMMP) Research & Development (2015 - 2017)

Immutep (IMMP) has reported Research & Development for 3 consecutive years, with -$2.3 million the latest figure, recorded in Q2 2017.

• For the quarter ending Q2 2017, Research & Development fell 94.7% year-over-year to -$2.3 million; the trailing twelve-month figure through Jun 2017 stood at -$5.9 million (changed N/A YoY), and the FY2026 full-year result was -$65.2 million, down 65.84% from the prior year.
• Research & Development slipped to -$2.3 million in Q2 2017 per IMMP's latest filing, from -$1.4 million in the prior quarter.
• Across five years, Research & Development topped out at -$4892.0 in Q2 2015 and bottomed at -$2.3 million in Q2 2017.
• Historically, Research & Development has averaged -$1.2 million across 3 years, with a median of -$1.2 million in 2016.
• The sharpest annual moves came in 2016 and 2017: Research & Development sank 23569.78% in 2016, then declined 27.11% in 2017.
• Over 3 years, Research & Development stood at -$4892.0 in 2015, then tumbled by 23569.78% to -$1.2 million in 2016, then tumbled by 94.7% to -$2.3 million in 2017.
• According to Business Quant data, Research & Development over the past three periods registered -$2.3 million, -$1.4 million, and -$1.2 million for Q2 2017, Q1 2017, and Q2 2016 respectively.